ArticleThe Journal of clinical investigation2012
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.
Cynthia X Ma et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
136 papers cite itlatest 60 shown
this paperpooled ittrialcites it